Maurice Perol retweeted
🔥Lung🫁 #ESMO26 #LCSM 🎉Again🔂
4⃣ @NEJM
🎯DeLLphi-305 🎯OptiTROP-Lung06
🎯Krascendo 1 🎯SAFFRON
2⃣ @TheLancet
🎯PANKU-Lung01 🎯HERON-Lung01
3⃣ @Annals_Oncology
🎯PERSEE 🎯DeLLphi-304 🎯NEOTORCH
1⃣ @Nature
🎯NeoCOAST-2
1⃣ @NatureMedicine
🎯MDT-BRIDGE
1⃣ @JCO_ASCO
🎯Dalmelitinib Plus Aumolertinib
@OncoAlert @Larvol @myESMO @IASLC @ASCO
@EGFRResisters @KRASKickers @metcrusaders
Maurice Perol retweeted
#ESMO26 One of my favorite discussant. Dr @JordiRemon discusses early stage immunotherapy abstracts. Many options in the neoadjuvant and perioperative space, summarized beautifully. What is the value of adjuvant immunotherapy? Is receipt of adjuvant therapy a surrogate for fitness? #ESMOAmbassadors
Maurice Perol retweeted
Pembro monotherapy still has a role in selected pts (borderline ECOG PS or where a pt does not want to do chemo) but the control arm did not underperform. The final median PFS for Pembro mono in KN024 was only 3 weeks less than the control arm performance in PERSEE was it not?
Maurice Perol retweeted
#ESMO26 | PERSEE
We expected chemotherapy to add benefit, but the magnitude of PFS improvement even in PD-L1 ≥90% patients is striking.
Despite the limitations of subgroup analyses, these findings challenge the routine preference for ICI monotherapy in this population.
#ESMO26 | PERSEE
For patients fit enough to tolerate chemotherapy, these results strengthen my preference for pembro + CT, even with very high PD-L1.
The sustained PFS benefit and encouraging OS separation deserve attention.
Heartfelt congratulations to the investigators for conducting this academic, multicentre trial addressing a question we face every day👏
Maurice Perol retweeted
🔥🚨@OncoAlert Hot off the press.
Just published @Annals_Oncology in conjunction with presentation @myESMO #ESMO26
results of:
⭐️#PERSEE phase 3 trial of:
❇️#Pembrolizumab monotherapy
Vs
#Pembrolizumab + #Chemotherapy
🎯For #1stLine Tx of advanced non-small-cell #LungCancer (#NSCLC) with HIGH #PDL1 (PD-L1 ≥50%).
Study showed:
‼️Statistically significant & clinically meaningful ⬆️#ProgressionFreeSurvival Benefit.
✅#mPFS: 16.1 vs 6.9 mo (HR 0.56)
❓#mOS: 50.2 vs 29.9 mo
NOT Statistical Significant
(HR 0.77; 95% CI, 0.56–1.05)
Study not powered for #OverallSurvival
👇🏻
annalsofoncology.org/article…
Maurice Perol retweeted
‼️ In first line treatment of advanced PD-L1 ≥50% NSCLC, PERSEE demonstrates a significant improvement of PFS with pembro-CT compared to pembro monotherapy regardless of PDL1 level of (over)expression. Practise changing trial. @myESMO @OncoAlert #ESMO26 👏👏👏 @decroisette
Maurice Perol retweeted
@myGFPC PRESEE trial is now presented by @decroisette #ESMO26. Publication in annals of oncology simultaneously !
So proup of our cooperative group 💪🇨🇵
Maurice Perol retweeted
Academic & pragmatic phase III trial (PERSEE) #ESMO26 reshaping therapeutic choices for PD-L1 high patients (including ultra-high PD-L1 80/90%). Convincing & impressive results.
Huge congrats to the GFPC group 🇫🇷 for leading this unique and crucial study! 👏@decroisette
Maurice Perol retweeted
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: nej.md/4iveIgW
@myESMO
ALT A graph from the Original Article "Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer." The trial name, DeLLphi-305, is in parentheses after the title. The graph shows the overall survival (intention-to-treat population). The trial results are being presented at the European Society For Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
Maurice Perol retweeted
🔥 TODAY COULD BE ONE OF THE DEFINING MOMENTS OF #ESMO26! 🔥
The ESMO Presidential Symposium is always one of the highlights of the congress, and today’s session promises some truly extraordinary science!
If I had to pick ONE study with the greatest potential to change clinical practice at ESMO 2026, my choice would be DeLLphi-305.
For decades, SCLC has been one of the most challenging diseases in oncology, with far too little progress and far too few therapeutic breakthroughs.
Could DeLLphi-305 finally represent the major leap forward we have been waiting for? We already know that adding tarlatamab to durvalumab as first-line maintenance significantly improves OS compared with durvalumab alone. But today, we will finally see the numbers. And I am genuinely excited to discover just how transformative this benefit might be! My personal bet for the biggest breakthrough of #ESMO26? DeLLphi-305. @StephenVLiu @sands_jacob
Of course, the magnitude of survival benefit, safety and clinical applicability will ultimately determine its impact. But the potential is enormous. Don’t miss today’s Presidential Symposium!
Madrid | 🕟 16:30 CEST Alicante auditorium
#ESMO26 #ESMOAmbassador #SCLC #LungCancer #Immunotherapy #Oncology #PracticeChanging
Maurice Perol retweeted
#ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1
In ES-SCLC, tarlatamab + durvalumab maintenance significantly improved outcomes vs durvalumab alone following first-line chemotherapy + durvalumab:
OS: 21.1 vs 12.7 months (HR 0.42)
PFS: 7.4 vs 1.9 months (HR 0.34)
CRS: 49.6%; grade ≥3: 0.4%.
An impressive OS benefit! Atezolizumab + lurbinectedin maintenance also demonstrated an OS benefit in IMforte (HR 0.73). Although cross-trial comparisons are inappropriate, the magnitude of the OS benefit with tarlatamab appears numerically much greater.
Maurice Perol retweeted
🚨 ESMO 2026 presidential | DeLLphi-305:
Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO.
📊 Key results:
• Median OS: 21.1 vs 12.7 months (HR 0.42) 🔥
• 12-month OS: 79.4% vs 53.3%
• Median PFS: 7.4 vs 1.9 months (HR 0.34)
• ORR: 26.4% vs 4.1%
⚠️ Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (mostly low grade).
💡 58% reduction in risk of death!
Could this redefine first-line maintenance in ES-SCLC? Probably yes. Looking forward towards full data set . @OncoAlert @esmo #esmo26 #SCLC #DeLLphi305
Maurice Perol retweeted
Hard not to add the PERSEE study, (a GFPC trial 🇫🇷) so eagerly awaited for our daily practice and so often cited for its design and the anticipation of its results (1st in place for the PD-L1 high patient strategy) which are finally here and truly impressive #ESMO26 ! 📈🔥
Maurice Perol retweeted
Superb French pragmatic study by the GFPC 🇫🇷 and the only one asking this crucial question: combination therapy vs. mono-pembro in our PD-L1 High patients! 👏
Kudos, and a top highlight from #ESMO26 for lung cancer 🫁✨
🆙#ESMO26 Proffered Paper I: #LCSM Mets
🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial
🎙️ @decroisette
🔢2614O
🎯Pembro-Chemo Improved BCR-PFS vs Pembro Alone
🎯PFS HR 0.56, mPFS 16.1 vs 6.9m
🎯OS HR 0.77 not significant; mOS 50.2 vs 29.9mo
🎯Grade≥3 TRAEs 53.8% vs 19.3%
☑️NCT04547504
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Maurice Perol retweeted
🆙 #ESMO26 Proffered Paper I: #LCSM Mets
🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial
🎙️ @decroisette
🔢2614O
☑️NCT04547504
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Maurice Perol retweeted
📢 #SCLC news: Amgen announced that a Phase 3 study evaluating its DLL3-targeting therapy as part of first-line maintenance treatment for patients with extensive-stage small cell lung cancer met its primary endpoint
➡️ Learn more: amgen.ly/4ihHq5p
$AMGN
Maurice Perol retweeted
Mark your calendars for the @IASLC 2026 Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy, June 26-27 in Dublin, Ireland! Very timely coming off major presentations and updates at #ASCO26.
ht26-iaslc.eventsair.site/
Maurice Perol retweeted
Adjuvant selpercatinib improves EFS for resected RET+ NSCLC. LIBRETTO-432 following ADAURA in EGFR and ALINA in ALK, as many have predicted. Looking forward to seeing the full data.
lilly.mediaroom.com/2026-02-…
Maurice Perol retweeted
UNREST sIII NSCLC is a new hot topic
-PACIFIC remains SoC
Efforts to improve but:
-Intensification IO consol ❌
-IO with CRT❌
-Promising data with i CTIO—>CRT🔆
Future:
*SKS03❓
*Borderline unresect —> Resect:
MDT Bridge❓ (ESMO)
*Lots of challenges ✳️
rdcu.be/eJ9Lj
